Analyst consensus rating
Upstream Bio Analyst Rating: none
Direct answer
Upstream Bio's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $31.14.
Forecast evidence checked October 17, 2026.
Get free Upstream Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.76
- Average price target
- $31.14
- High price target
- $75.00
- Low price target
- $9.00
- Low target gap
- +226.1%
- Target upside
- +1,028.4%
- High target gap
- +2,617.4%
- Target range width
- 2,391.3%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Upstream Bio?
Upstream Bio has a verified none consensus. The same dataset has an average price target of $31.14.
How far are Upstream Bio's low and high targets from the recorded price?
The low target implies +226.1%, while the high target implies +2,617.4%.
How many analysts are included in Upstream Bio's consensus?
The verified consensus includes 7 analysts.
How is Upstream Bio's target upside or downside calculated?
The average target of $31.14 is divided by the recorded price of $2.76, then one is subtracted to produce +1,028.4%. This does not guarantee a future return.
When was Upstream Bio's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.